John Cox
Directeur Général chez DYNE THERAPEUTICS, INC.
Fortune : 205 069 $ au 31/07/2023
Profil
John G.
Cox is currently the President, Chief Executive Officer & Director at Dyne Therapeutics, Inc. He is also the Chairman at Minovia Therapeutics Ltd.
and a Director at Torque Therapeutics, Inc. Previously, Mr. Cox served as the Chief Executive Officer & Director at Repertoire Immune Medicines, Inc. from 2019 to 2022.
He was also the Chief Executive Officer & Director at Bioverativ, Inc. from 2017 to 2018.
Additionally, he served as an Independent Director at Repligen Corp.
from 2013 to 2020.
Mr. Cox has also held positions as a Director at Samsung Bioepis Co., Ltd., an Independent Director at Sigilon Therapeutics, Inc. from 2019 to 2023, and as a Principal at Wyeth LLC from 1993 to 2000.
He was the EVP-Global Commercial & Technical Operations at Biogen, Inc. from 2016 to 2017 and a Principal at Covance Biotechnology Services, Inc. in 2003.
He also worked as an Executive Vice President at Biogen Idec New Ventures, Inc. In terms of education, Mr. Cox completed his undergraduate degree at Arizona State University.
He pursued his graduate studies at The California State University and obtained an MBA from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DYNE THERAPEUTICS INC
0,01% | 31/03/2024 | 5 000 ( 0,01% ) | 176 450 $ | 30/06/2024 |
| 11/08/2023 | 1 368 ( 0,05% ) | 28 619 $ | 31/07/2023 |
Postes actifs de John Cox
| Sociétés | Poste | Début |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Directeur Général | 25/03/2024 |
Torque Therapeutics, Inc.
 Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Président | 01/02/2019 |
Anciens postes connus de John Cox
| Sociétés | Poste | Fin |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Directeur/Membre du Conseil | 11/08/2023 |
Repertoire Immune Medicines, Inc.
 Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Directeur Général | 06/11/2022 |
| REPLIGEN CORPORATION | Directeur/Membre du Conseil | 13/05/2020 |
| BIOVERATIV INC | Directeur Général | 01/01/2018 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2017 |
Formation de John Cox
| University of Michigan | Masters Business Admin |
| The California State University | Graduate Degree |
| Arizona State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| REPLIGEN CORPORATION | Health Technology |
| SIGILON THERAPEUTICS, INC. | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ. | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. | Health Technology |
Samsung Bioepis Co., Ltd.
 Samsung Bioepis Co., Ltd. Pharmaceuticals: MajorHealth Technology Samsung Bioepis Co., Ltd. manufactures biopharmaceutical products. The company was founded on February 28, 2012 and is headquartered in Incheon, South Korea. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Commercial Services |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Health Technology |
